drugset / Trial / NCT04697888

Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease

NCT04697888

Phase 2/3 Completed 2 enrolled Children's Mercy Hospital Kansas City
NaSingle-groupOpen-labelTreatment

Summary

To provide parenteral fat emulsion prepared from fish oil (omega-3 fatty acid emulsion, Omegaven®) to patients with liver disease (PNALD).

Timeline

Start
2013-04
Primary completion
2018-11
Completion
2018-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Omegaven Other / unclassified 1 g/kg Intravenous